Recent News

• 09.15.2025 - Stifel 2025 Virtual Immunology and Inflammation Forum
• 09.15.2025 - Stifel 2025 Virtual Immunology and Inflammation Forum
• 09.15.2025 - Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
• 09.15.2025 - Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
• 09.02.2025 - Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
• 09.02.2025 - Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
• 08.07.2025 - Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates
• 08.07.2025 - Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates
• 07.21.2025 - Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
• 07.21.2025 - Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

Recent Filings

• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2025 - 8-K Current report
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2025 - EX-99.1 EX-99.1
• 06.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.16.2025 - 4 Statement of changes in beneficial ownership of securities